These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 34344239)

  • 41. Anticancer effects of the Hsp90 inhibitor 17-demethoxy-reblastatin in human breast cancer MDA-MB-231 cells.
    Zhao Q; Wu CZ; Lee JK; Zhao SR; Li HM; Huo Q; Ma T; Zhang J; Hong YS; Liu H
    J Microbiol Biotechnol; 2014 Jul; 24(7):914-20. PubMed ID: 24705874
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Geldanamycin inhibits tyrosine phosphorylation-dependent NF-kappaB activation.
    Crèvecoeur J; Merville MP; Piette J; Gloire G
    Biochem Pharmacol; 2008 Jun; 75(11):2183-91. PubMed ID: 18455150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. New non-quinone geldanamycin analogs from genetically engineered Streptomyces hygroscopicus.
    Wu CZ; Moon AN; Jang JH; Lee D; Kang SY; Park JT; Ahn JS; Hwang BY; Kim YH; Lee HS; Hong YS
    J Antibiot (Tokyo); 2011 Jun; 64(6):461-3. PubMed ID: 21448187
    [No Abstract]   [Full Text] [Related]  

  • 44. Enzyme specific activation of benzoquinone ansamycin prodrugs using HuCC49DeltaCH2-beta-galactosidase conjugates.
    Fang L; Battisti RF; Cheng H; Reigan P; Xin Y; Shen J; Ross D; Chan KK; Martin EW; Wang PG; Sun D
    J Med Chem; 2006 Oct; 49(21):6290-7. PubMed ID: 17034135
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The missing C-17 O-methyltransferase in geldanamycin biosynthesis.
    Yin M; Lu T; Zhao LX; Chen Y; Huang SX; Lohman JR; Xu LH; Jiang CL; Shen B
    Org Lett; 2011 Jul; 13(14):3726-9. PubMed ID: 21682254
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Dihydroquinone ansamycins: toward resolving the conflict between low in vitro affinity and high cellular potency of geldanamycin derivatives.
    Maroney AC; Marugan JJ; Mezzasalma TM; Barnakov AN; Garrabrant TA; Weaner LE; Jones WJ; Barnakova LA; Koblish HK; Todd MJ; Masucci JA; Deckman IC; Galemmo RA; Johnson DL
    Biochemistry; 2006 May; 45(17):5678-85. PubMed ID: 16634649
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Lipophilic prodrugs of Hsp90 inhibitor geldanamycin for nanoencapsulation in poly(ethylene glycol)-b-poly(epsilon-caprolactone) micelles.
    Forrest ML; Zhao A; Won CY; Malick AW; Kwon GS
    J Control Release; 2006 Nov; 116(2):139-49. PubMed ID: 16926059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-based and in silico design of Hsp90 inhibitors.
    Sgobba M; Rastelli G
    ChemMedChem; 2009 Sep; 4(9):1399-409. PubMed ID: 19685544
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
    Schwock J; Pham NA; Cao MP; Hedley DW
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J; Eichner S; Zeilinger C; Kirschning A
    Nat Prod Rep; 2013 Oct; 30(10):1299-323. PubMed ID: 23934201
    [TBL] [Abstract][Full Text] [Related]  

  • 51. New, non-quinone fluorogeldanamycin derivatives strongly inhibit Hsp90.
    Hermane J; Bułyszko I; Eichner S; Sasse F; Collisi W; Poso A; Schax E; Walter JG; Scheper T; Kock K; Herrmann C; Aliuos P; Reuter G; Zeilinger C; Kirschning A
    Chembiochem; 2015 Jan; 16(2):302-11. PubMed ID: 25572106
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
    Smith MA; Morton CL; Phelps DA; Kolb EA; Lock R; Carol H; Reynolds CP; Maris JM; Keir ST; Wu J; Houghton PJ
    Pediatr Blood Cancer; 2008 Jul; 51(1):34-41. PubMed ID: 18260120
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The interplay between mutasynthesis and semisynthesis: generation and evaluation of an ansamitocin library.
    Eichner S; Knobloch T; Floss HG; Fohrer J; Harmrolfs K; Hermane J; Schulz A; Sasse F; Spiteller P; Taft F; Kirschning A
    Angew Chem Int Ed Engl; 2012 Jan; 51(3):752-7. PubMed ID: 22135226
    [No Abstract]   [Full Text] [Related]  

  • 54. Targeting HSP90 Gene Expression with 17-DMAG Nanoparticles in Breast Cancer Cells.
    Mellatyar H; Talaei S; Nejati-Koshki K; Akbarzadeh A
    Asian Pac J Cancer Prev; 2016; 17(5):2453-7. PubMed ID: 27268613
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Mitotic catastrophe cell death induced by heat shock protein 90 inhibitor in BRCA1-deficient breast cancer cell lines.
    Zajac M; Moneo MV; Carnero A; Benitez J; Martínez-Delgado B
    Mol Cancer Ther; 2008 Aug; 7(8):2358-66. PubMed ID: 18723483
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Synthesis and biological evaluation of novel aliphatic amido-quaternary ammonium salts for anticancer chemotherapy: part II.
    Yang JS; Song D; Ko WJ; Kim B; Kim BK; Park SK; Won M; Lee K; Lee K; Kim HM; Han G
    Eur J Med Chem; 2013 May; 63():621-8. PubMed ID: 23567950
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer.
    Weber H; Valbuena JR; Barbhuiya MA; Stein S; Kunkel H; García P; Bizama C; Riquelme I; Espinoza JA; Kurtz SE; Tyner JW; Calderon JF; Corvalán AH; Grez M; Pandey A; Leal-Rojas P; Roa JC
    Oncotarget; 2017 Apr; 8(16):26169-26184. PubMed ID: 28412732
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
    Grover A; Shandilya A; Agrawal V; Pratik P; Bhasme D; Bisaria VS; Sundar D
    Biochem Biophys Res Commun; 2011 Jan; 404(1):498-503. PubMed ID: 21144839
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of 4,5-dihydro-4-hydroxygeldanamycins as shunt products of geldanamycin biosynthesis.
    Li T; Ni S; Jia C; Wang H; Sun G; Wu L; Gan M; Shan G; He W; Lin L; Zhou H; Wang Y
    J Nat Prod; 2012 Aug; 75(8):1480-4. PubMed ID: 22849774
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A novel class of geldanamycin derivatives as HCV replication inhibitors targeting on Hsp90: synthesis, structure-activity relationships and anti-HCV activity in GS4.3 replicon cells.
    Shan GZ; Peng ZG; Li YH; Li D; Li YP; Meng S; Gao LY; Jiang JD; Li ZR
    J Antibiot (Tokyo); 2011 Feb; 64(2):177-82. PubMed ID: 21179047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.